Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation

This study has been completed.
Sponsor:
Information provided by:
Valduce Hospital
ClinicalTrials.gov Identifier:
NCT00933634
First received: July 2, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted
  Purpose

The optimal strategy to restore sinus rhythm in patients with atrial fibrillation (AF) of less than 48 hours' duration is still controversial. The investigators performed a controlled single-center trial to compare electrical and pharmacological (propafenone) cardioversion to restore the sinus rhythm in selected patients with acute atrial fibrillation.


Condition Intervention
Atrial Fibrillation
Procedure: electrical cardioversion
Drug: propafenone

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation: a Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by Valduce Hospital:

Primary Outcome Measures:
  • Efficacy of intervention (Electrical and pharmacological cardioversion) in restoring sinus rythm [ Time Frame: during emergency department stay ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of adverse events related to electrical and pharmacological cardioversion [ Time Frame: during emergency department stay ] [ Designated as safety issue: Yes ]
  • recurrence of atrial fibrillation [ Time Frame: within 2 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 247
Study Start Date: January 2006
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: electrical cardioversion
Patients were sedated with propofol and external cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula). Patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
Procedure: electrical cardioversion
External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
Active Comparator: propafenone
Propafenone (2 mg/kg bolus) was administered iv to obtain pharmacologic sinus rhythm conversion.
Drug: propafenone
Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • atrial fibrillation of less than 48 hours' duration.

Exclusion Criteria:

  • AF of more than 48 hours'
  • hemodynamic instability
  • acute onset atrial fibrillation due to acute coronary syndrome
  • electrolyte disturbances
  • sepsis
  • fever
  • hypothermia
  • untreated hyperthyroidism
  • use of antiarrhythmic drugs
  • high embolic risk
  • unclear duration of symptoms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00933634

Locations
Italy
Emergency Unit - Valduce Hospital
Como, Italy, 22100
Sponsors and Collaborators
Valduce Hospital
  More Information

No publications provided by Valduce Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Andrea Bellone, Valduce Hospital
ClinicalTrials.gov Identifier: NCT00933634     History of Changes
Other Study ID Numbers: ECVPCV-001
Study First Received: July 2, 2009
Last Updated: July 2, 2009
Health Authority: Italy: Ethics Committee

Keywords provided by Valduce Hospital:
atrial fibrillation
electrical cardioversion
pharmacological cardioversion

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Atrial Fibrillation
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Propafenone
Anti-Arrhythmia Agents
Cardiovascular Agents
Membrane Transport Modulators
Sodium Channel Blockers
Therapeutic Uses
Voltage-Gated Sodium Channel Blockers

ClinicalTrials.gov processed this record on November 27, 2014